Helix BioPharma (TSE:HBP) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Helix BioPharma Corp. has entered into a non-binding letter of intent to acquire the oncology assets of Laevoroc Group, potentially enhancing their immuno-oncology portfolio. The acquisition includes a novel oral chemotherapy formulation and a preclinical immune checkpoint inhibitor, which could simplify cancer treatment and offer new hope for leukemia patients.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.